<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00231309</url>
  </required_header>
  <id_info>
    <org_study_id>0561-2003</org_study_id>
    <nct_id>NCT00231309</nct_id>
  </id_info>
  <brief_title>Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT)</brief_title>
  <official_title>Pilot Study of Using Granulocyte Colony Stimulating Factor-Primed Bone Marrow in Histocompatible Sibling Allogeneic Bone Marrow Transplantation for Patients With Hematologic Malignancies and Non-Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The major purpose of this study is to evaluate the curative potential of white cell growth
      hormone (G-CSF)-stimulated bone marrow cells in allogeneic bone marrow transplants. Patients
      with cancers or blood diseases, who have poor potential for a cure with standard treatment,
      will be able to participate in the study. Donors will receive the white cell growth hormone
      (G-CSF) as a shot (injection) in their arm once a day for three days before they donate their
      bone marrow cells. Total body irradiation and/or chemotherapy will be given first to prepare
      the patient's body for the infusion of new bone marrow cells from the donor. Two medicines
      (cyclosporine and methotrexate) will be used to prevent the new bone marrow cells (graft)
      from attacking the patient's body (host) (graft-versus-host disease; GVHD). Certain safety
      checkpoints were built into the study if unwanted/unexpected events were to occur. If the
      outcomes appear better than could be expected, this will provide a bridge to extend this
      current approach for other innovative therapies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-arm, non-randomized trial. Patients meeting the criteria for this
      study will be entered sequentially until completion or closure of the study. Early stopping
      rules will be employed to ascertain whether an unacceptable rate of toxicity
      (non-engraftment, and/or acute GvHD) occurs.

      Patients will be prepared for transplant through the administration of one of the following
      conditioning regimen based on his/her primary disease:

      5.1 Total body irradiation 1200 rads in 6 fractionated doses and high dose chemotherapy,
      including etoposide and cyclophosphamide.

      5.2 High dose chemotherapy with busulfan and cyclophosphamide. 5.2.1 Patients who are not
      candidates for TBI will receive chemotherapy-based conditioning regimen.

      5.3 Post transplant immunosuppression prophylaxis against acute GVHD will include
      cyclosporine and methotrexate.

      5.4 Donor will receive 3 daily G-CSF injections (starting on day -3) prior to marrow harvest.
      The injections may be initiated by the donor's primary physician prior to donor's arrival
      here, or by BMT service at Children's Healthcare of Atlanta.

      5.5 Patients will receive daily G-CSF injections (5 mcg/kg) starting from day+5 post
      transplant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Numbers of Participants With Disease-free Survival.</measure>
    <time_frame>260 days</time_frame>
    <description>Evaluate the numbers of participants with disease-free survival</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay</measure>
    <time_frame>inpatient hospital stay</time_frame>
    <description>hospital length of stay of each patient enrolled, an average of 5 weeks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hematologic Diseases</condition>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte Colony Stimulating Factor</intervention_name>
    <description>Granulocyte Colony Stimulating Factor</description>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hematologic malignancies and non-malignancies who are candidates for
             matched sibling donor allogeneic bone marrow transplantation are eligible for this
             study.

          -  Patients who are under 55 years of age.

          -  Patients who have a life expectancy of at least 12 weeks and a performance status of
             at least 2 Zubrod or 70% Karnofsky status prior to transplantation.

          -  Patients who are acceptable candidates for marrow transplantation based on their
             pre-BMT evaluation.

          -  Patients who have available histocompatible siblings who have been medically approved
             as marrow donors.

          -  Patients who sign informed consent for the protocol approved by the Institutional
             Review Board of Emory University/Children's Healthcare of Atlanta.

          -  Donors must be 5 years of age or older, and have completed routine donor evaluations
             and signed (by parent or legal guardian) informed consent for the protocol approved by
             the Institutional Review Board of Emory University/Children's Healthcare of Atlanta.

        Exclusion Criteria:

          -  Patients will not be excluded based on sex, racial, or ethnic background.

          -  Patients will be excluded if they demonstrate significant functional deficits in major
             organs, which would obviously interfere with a successful outcome following bone
             marrow transplant utilizing the following guidelines:

               -  Evidence of active, deep seated, life-threatening infections for which there is
                  no known effective therapy (e.g. certain fungal species, HIV, etc.).

               -  Patients with hemoglobinopathy (e.g. sickle cell disease and thalassemia) will
                  not be eligible for this protocol. However, filgrastim mobilization, large volume
                  apheresis, processing, and cryopreservation appears to be safe in donors with
                  sickle cell trait.

               -  Patients have had greater than two leukemic episodes, active central nervous
                  system (CNS) and/or leukemic disease and blast crisis in chronic myelogenous
                  leukemia (CML) patients.

          -  Patients will be excluded if they are women of childbearing potential who are
             currently pregnant (beta-hCG+) or who are not practicing adequate contraception.

          -  Patients who have had previous stem cell transplant will be excluded.

          -  Donors will be excluded if they are sensitive to E. coli-derived protein.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuang-Yueh Chiang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University/CHOA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta/Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2005</study_first_submitted>
  <study_first_submitted_qc>October 3, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2005</study_first_posted>
  <results_first_submitted>August 14, 2013</results_first_submitted>
  <results_first_submitted_qc>July 31, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2014</results_first_posted>
  <last_update_submitted>August 19, 2014</last_update_submitted>
  <last_update_submitted_qc>August 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Kuang-Yueh Chiang</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>G-CSF</keyword>
  <keyword>Bone Marrow</keyword>
  <keyword>Hematologic malignancies</keyword>
  <keyword>Non-malignancies</keyword>
  <keyword>Matched sibling donor</keyword>
  <keyword>Allogeneic BMT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>10 patients were enrolled between July 2003 and March 2006. Patients were enrolled during consent visits for upcoming bone marrow transplants.</recruitment_details>
      <pre_assignment_details>Patients were not excluded before assignment to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Granulocyte Colony Stimulating Factor</title>
          <description>Granulocyte Colony Stimulating Factor : Granulocyte Colony Stimulating Factor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm</title>
          <description>Granulocyte Colony Stimulating Factor : Granulocyte Colony Stimulating Factor</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.47" spread="4.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Numbers of Participants With Disease-free Survival.</title>
        <description>Evaluate the numbers of participants with disease-free survival</description>
        <time_frame>260 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Granulocyte-stimulating Factor</title>
            <description>Granulocyte Colony Stimulating Factor : Granulocyte Colony Stimulating Factor</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Participants With Disease-free Survival.</title>
          <description>Evaluate the numbers of participants with disease-free survival</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay</title>
        <description>hospital length of stay of each patient enrolled, an average of 5 weeks.</description>
        <time_frame>inpatient hospital stay</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Granulocyte Colony Stimulating Factor</title>
            <description>Granulocyte Colony Stimulating Factor : Granulocyte Colony Stimulating Factor</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay</title>
          <description>hospital length of stay of each patient enrolled, an average of 5 weeks.</description>
          <units>average days</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" spread="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>260 days.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single Arm</title>
          <description>Granulocyte Colony Stimulating Factor : Granulocyte Colony Stimulating Factor</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Our study is also limited by its small patient population and short follow-up time.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Kuang-Yueh Chiang, MD</name_or_title>
      <organization>Emory University</organization>
      <phone>404-785-1441</phone>
      <email>kuang-yueh.chiang@choa.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

